Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00252564 · ClinicalTrials.gov registry record · Phase 3
Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer
A Phase 3 study, sponsored by US Oncology Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 247
- Enrollment target
NCT00252564 is a Phase 3 study that has completed, run by US Oncology Research. The registered enrollment target is 247 participants.
The verdict
NCT00252564, a Phase 3 study, has completed, sponsored by US Oncology Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 247 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the rates of Progression-Free Survival (PFS) at 12 months for patients treated with Bev-FOLFOX versus patients treated with FOLF-CB for first line treatment of metastatic colorectal cancer.
Interventions
- DRUG Bevacizumab
- DRUG Fluorouracil
- DRUG Leucovorin
- DRUG Oxaliplatin
- DRUG Cetuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 247 participants |
| Start Date | 2005-09 |
| Est. Completion | 2009-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00252564
The ClinicalTrials.gov registry entry for NCT00252564 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 247 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is US Oncology Research, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Bevacizumab is the first listed.
NCT00252564 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00252564 about?
NCT00252564 is a clinical study titled "Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer". The purpose of this study is to compare the rates of Progression-Free Survival (PFS) at 12 months for patients treated with Bev-FOLFOX versus patients treated with FOLF-CB for first line treatment of metastatic colorectal cancer.
What is the current status of trial NCT00252564?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 247 participants. The study started on 2005-09. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00252564?
The interventions under investigation include: Bevacizumab (DRUG), Fluorouracil (DRUG), Leucovorin (DRUG), Oxaliplatin (DRUG), Cetuximab (DRUG).
Who is sponsoring clinical trial NCT00252564?
This trial is sponsored by US Oncology Research, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.